At the heart of the Oncopole of Toulouse, the CRCT, together with all its partners (institutional, academic, clinical, industrial, charities…), stimulates innovation in terms of research and teaching in the fight against cancer.
The CRCT is a joint Research Unit Inserm & University Toulouse III Paul Sabatier
3 research teams are also labelled by the CNRS
Researchers, clinicians and supports
PhD students and post-doctoral fellows
Acute myeloid leukemias are cancers of the blood and bone marrow that are difficult to treat today because of the resistance of cancer cells to therapy. Currently, the 5-year survival rate is only about 30-40% in patients under 60 and 20-25% in patients over 60....
Treatment of testicular cancers with high doses of etoposide: impact of the elimination capacities of the drug and the genetic characteristics of the patient on the efficacy and toxicity of the treatment
For patients with refractory or relapsing testicular cancer after standard chemotherapy, more aggressive chemotherapy with carboplatin and etoposide may be used. After this high-dose chemotherapy, a stem cell transplant is performed to replace those that have been...
The 5,6-epoxycholesterol metabolic pathway in breast cancer: emergence of new pharmacological targets
Metabolic pathways have emerged as cornerstones in carcinogenic deregulation providing new therapeutic strategies for cancer management. This is illustrated by the recent discovery of a cholesterol metabolic branch involving the biochemical transformation of...
Centre de Recherches en Cancérologie de Toulouse
2 avenue Hubert Curien
31037 TOULOUSE CEDEX 1 – FRANCE